Bryan Leaw

Bryan completed his PhD in Neuroscience at the Florey Institute of Neuroscience & Mental Health studying childhood genetic epilepsies, discovering a novel disease pathway involving brain cell "branching" leading to seizures, and identifying novel anti-epileptic drugs. His PhD thesis was nominated for the Chancellor's Prize.

As a postdoctoral researcher at the Hudson Institute of Medical Research, Bryan focused on allogeneic stem cell therapies in neurological conditions such as cerebral palsy, and randomized clinical trials. Bryan’s research has been published in prestigious journals ranked top of their field, including Brain and the Journal of Clinical Investigation. He was also lead chief investigator on a substantial project grant.

Bryan utilizes his deep technical experience to tailor commercial and IP strategies for his clients, ranging from start-ups, SMEs to multi-national pharmaceutical and biotech companies. Bryan has experience in competitive landscape analysis, providing insights on both existing and emerging competitors to inform IP strategy. He has also prepared due diligence reports for venture capital investors and advised clients in providing investors updates to the share market.

Bryan also believes in giving back to the academic research sector, having been a researcher himself. He has been invited to speak numerous times to early career researchers on alternative career pathways, as well as mentored and assisted in entrepreneurship events, including the 3 Day Startup and UHack.

An ethos Bryan subscribes to is “bench to bedside” – taking research findings in the lab to create tangible products that benefit patients – treating previously incurable diseases and improving patients’ quality of life.

Bryan is a registered Australian and New Zealand Patent Attorney.